A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The study involves a single dose of a study drug called abemaciclib taken by mouth. The
purpose of this study will be to measure how much study drug gets into the blood stream and
how long the body takes to get rid of it when given to participants with mild, moderate, or
severe liver impairment compared to healthy participants. In addition, the tolerability of
the study drug will be evaluated.
This study will last approximately 3 weeks for each participant, including check-in and
follow-up.